Retatrutide
Technical Monograph
Retatrutide (LY3437943) is an advanced, synthetically modified 39-amino-acid peptide acting as a tri-agonist for the gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and native glucagon (GCG) receptors. Uniquely engineered to maximize energy expenditure directly alongside appetite suppression, it represents the leading edge of multi-receptor incretin mimetics.
Mechanism of Action
Retatrutide activates GIP, GLP-1, and surprisingly, Glucagon (GCG) pathways. While GIP and GLP-1 activation produces classical suppression of systemic caloric intake and enhances insulin action, the integration of GCG receptor activation uniquely stimulates hepatic lipid metabolism and dramatically increases total basal energy expenditure through increased oxidative phosphorylation and thermogenesis.
Pharmacological Detail
Binds to human GLP-1, GIP, and GCG receptors. The GCG engagement forces accelerated glycogenolysis and gluconeogenesis, yet the overwhelming insulinotropic response initiated by the GIP/GLP-1 components neutralizes any hyperglycemic spikes.
Pharmacodynamics
Causes extreme systemic lipid mobilization, severe reductions in caloric hunger drive, and forced elevations of resting metabolic rate.
Pharmacokinetics
Highly bound to circulating albumin. Exhibits a terminal half-life permitting once-weekly sustained-release dosing (approximately 140 hours).
Preclinical Observations & In Vitro Data
Unprecedented lipid clearance and weight reduction velocity in preclinical models compared to legacy incretin therapies.
Observed Timeline of Action
| Timeframe | Pharmacological Effect |
|---|---|
| 24-48 hours | Onset of initial profound satiety markers. |
| Weeks 4-12 | Rapid, continuous depletion of visceral and subcutaneous lipid deposits. |
| Weeks 48+ | Approaches a 24-25% total body mass reduction plateau based on modeled extrapolations. |
Abstract Highlights
- Demonstrates functional tri-agonism, providing a significant mechanistic leap over mono- or dual-agonists
- GCG pathway engagement specifically targets hepatic steatosis and forces total energy expenditure independent of physical stimulation
- Features a highly modified backbone with a C20 fatty diacid and specialized linker to extend circulating half-life robustly
References
Chemical Specifications
Material Handling & Stability
Strict Notice
THIS COMPOUND IS PRODUCED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION. MATERIAL DATA SHEETS AND LABORATORY GUIDELINES SHOULD BE CONSULTED PRIOR TO HANDLING.